Atara Biotherapeutics Deferred Revenue 2011-2026 | ATRA

Deferred revenue is the amount of money or obligations that a company has received in advance for goods or services that have not yet been delivered or performed. In other words, it is income that has already been received but has not yet been recognized in accounting as revenue because the goods or services have not yet been transferred to the customer.

Features of the metric

Sources of future cash inflows
A high level of deferred revenue indicates that the company has secured future cash flows, which positively affects forecasts of its financial condition and stability.
Assessment of operational stability
Deferred revenue reflects demand for the company’s products or services and its ability to attract customers willing to pay in advance. It is one of the indicators of business stability and its competitive advantages.
Risks and obligations
Although deferred revenue indicates future inflows, it also represents obligations that the company must fulfill. If fulfilling these obligations is delayed or impossible, it can negatively impact reputation and financial results.
Analysis of liquidity and cash flow
Inflows in the form of deferred revenue improve the company’s current liquidity since the funds are already in the accounts. However, investors need to assess the ratio of deferred revenue to fulfilled obligations to understand the actual financial capabilities and risks.
Impact on company valuation
In fundamental analysis, deferred revenue is taken into account for accurate revenue and profit forecasting, especially in industries with long-term contracts or subscriptions (e.g., IT sector, services, manufacturing).

Quarterly Deferred Revenue Atara Biotherapeutics

2025-Q3	2025-Q2	2025-Q1	2024-Q4	2024-Q3	2024-Q2	2024-Q1	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	31.2 M	41 M	35.5 M	33.5 M	-	33.5 M	33.5 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
41 M	31.2 M	34.7 M

Deferred Revenue of other stocks in the Biotechnology industry

Issuer	Deferred Revenue	Price	% 24h	Market Cap	Country
MorphoSys AG MOR	86.5 M	-	2.43 %	$ 254 M	Germany
Processa Pharmaceuticals PCSA	58.2 K	$ 2.3	-1.29 %	$ 3.01 M	USA
Aeterna Zentaris AEZS	2.19 M	-	5.93 %	$ 314 M	Canada
I-Mab IMAB	563 K	-	-	$ 866 M	China
Alexion Pharmaceuticals, Inc. ALXN	15.9 M	-	-	$ 40.3 B	USA
Genfit SA GNFT	124 K	-	2.54 %	$ 160 B	France
Ascendis Pharma A/S ASND	363 K	$ 220.9	2.49 %	$ 5 B	Danmark
Midatech Pharma plc MTP	1.3 M	-	-18.52 %	$ 27.3 M	Britain
EyeGate Pharmaceuticals, Inc. EYEG	2.69 M	-	-1.52 %	$ 24.7 M	USA
Amphastar Pharmaceuticals AMPH	643 K	$ 19.57	1.77 %	$ 915 M	USA
Applied Genetic Technologies Corporation AGTC	6.3 M	-	-	$ 26.5 M	USA
Phathom Pharmaceuticals PHAT	27.2 M	$ 10.47	4.08 %	$ 763 M	USA
AgeX Therapeutics AGE	283 K	-	-10.17 %	$ 12.2 K	USA
Acorda Therapeutics ACOR	227 K	-	-24.86 %	$ 820 K	USA
BeiGene, Ltd. BGNE	187 M	-	0.49 %	$ 251 B	Cayman-islands
bluebird bio BLUE	2.28 M	-	-	$ 546 M	USA
Cara Therapeutics CARA	22.3 M	-	-3.03 %	$ 260 M	USA
Adverum Biotechnologies ADVM	1.85 M	-	-	$ 86.2 M	USA
Acer Therapeutics ACER	2.91 M	-	2.71 %	$ 14 M	USA
Advaxis ADXS	165 K	-	-9.65 %	$ 45.9 M	USA
Corbus Pharmaceuticals Holdings CRBP	1.46 M	$ 8.31	1.59 %	$ 111 M	USA
CRISPR Therapeutics AG CRSP	15.8 M	$ 47.09	1.42 %	$ 4.23 B	Schweiz
ChemoCentryx CCXI	11 M	-	-	$ 3.74 B	USA
Prelude Therapeutics Incorporated PRLD	33.7 M	$ 3.26	4.49 %	$ 251 M	USA
Dynavax Technologies Corporation DVAX	2.65 M	-	-	$ 2.02 B	USA
ProQR Therapeutics N.V. PRQR	700 K	$ 1.58	6.04 %	$ 99.5 M	Niderland
BioDelivery Sciences International BDSI	1.72 M	-	-4.8 %	$ 255 M	USA
Aeglea BioTherapeutics AGLE	517 K	-	-	$ 1.01 B	USA
CureVac N.V. CVAC	158 M	-	-	$ 867 M	Germany
Palatin Technologies PTN	35.1 M	$ 21.0	5.79 %	$ 19.5 M	USA
Pulmatrix PULM	618 K	$ 2.12	-1.4 %	$ 7.74 M	USA
Arbutus Biopharma Corporation ABUS	7.57 M	$ 4.53	5.1 %	$ 868 M	Canada
Homology Medicines FIXX	1.16 M	-	0.77 %	$ 53.4 M	USA